ANNUAL REPORT 2012

A MEDICAL VISION AND INTERNATIONAL OUTLOOK
AT THE HEART OF WHAT WE DO
<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>p. 02</td>
<td>INTERVIEW</td>
</tr>
<tr>
<td>p. 04</td>
<td>NEW PRODUCTS</td>
</tr>
<tr>
<td>p. 12</td>
<td>INNOVATION</td>
</tr>
<tr>
<td>p. 16</td>
<td>INTERNATIONAL</td>
</tr>
<tr>
<td>p. 20</td>
<td>CORPORATE RESPONSIBILITY</td>
</tr>
<tr>
<td>p. 28</td>
<td>CORPORATE GOVERNANCE</td>
</tr>
<tr>
<td>p. 30</td>
<td>FINANCIAL RESULTS</td>
</tr>
<tr>
<td>p. 35</td>
<td>THE BIOMÉRIEURS SHARE</td>
</tr>
<tr>
<td>p. 36</td>
<td>GLOSSARY</td>
</tr>
</tbody>
</table>
A world leader in the field of *in vitro* diagnostics for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2012, revenues reached €1.570 billion with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market.
What major trends have shaped 2012?

With sales of €1,570 million, representing growth of 6.8% at constant exchange rates, we met our objectives. Our operating income before non-recurring items reached €260 million, with our performance closely tied to the rigorous implementation of our actions across all areas. These results attest to both the robustness of our model and the competitiveness of bioMérieux.

I would also like to emphasize that we hold a unique position in the field of in vitro diagnostics, a promising market that should represent €55 billion within the next 5 years, given that numerous medical needs still remain unmet. Seventy percent of our income was generated in activities where we are world leaders, i.e., clinical microbiology and industrial microbiology applications, two areas where we have undeniable expertise and experience grounded in our history.

Our leadership has been further strengthened by the recent acquisitions of ARGENE, specialized in molecular biology and AES, in industrial applications, two companies that have been successfully integrated over the course of 2012, and whose positive impact can be felt today.

Speaking of competitiveness, how did bioMérieux fare in 2012?

Two pillars form the foundation of our competitiveness: our innovation strategy and an especially extensive and balanced international network.

Our competitiveness is also driven by a strategy of targeted acquisitions and partnerships, enabling us to enrich our areas of specialization and to develop new, multidisciplinary approaches, which are essential for our business today.

In 2012, thanks to our innovation programs, we launched 19 new products across all our product ranges, and in 2013 we will introduce three new systems: an incubator incorporating differentiating imaging technologies, a new automated blood culture system and VIDAS® 3, the new generation VIDAS®.

We ensure that these solutions are available for biologists internationally thanks to our strong commercial network, which was enriched in 2012 with the addition of two new commercial subsidiaries, in Malaysia and Vietnam, bringing the number of our subsidiaries worldwide to 41.

“A medical vision and international outlook at the heart of what we do”
INTERVIEW

WITH JEAN-LUC BELINGARD
CHAIRMAN AND CEO

In terms of innovation, what are your priorities?

Above all, our priorities are driven by our medical vision which is to deliver diagnostic solutions that will contribute to improving patient care by providing information that is increasingly comprehensive, relevant and rapid, with proven clinical benefits. These solutions must also meet major public healthcare challenges for example, combating antibiotic resistant bacteria, which is a major global threat.

Our agreement with Quanterix in 2012 is just one example. It will allow us to develop a new generation of immunoassays that are ultrasensitive and particularly rapid, with performances comparable to that of molecular biology methods. Hence, we will provide new high medical value solutions in both clinical and industrial applications.

We also intend to contribute to improving the operational efficiency of laboratories and the economic viability of healthcare systems, which is why our offering of Full Microbiology Laboratory Automation (FMLA®) is so important. More generally, in the framework of current economic difficulties, diagnostics has a key role to play in helping to make healthcare systems more efficient and in controlling healthcare costs.

What do you mean by medical vision?

Diagnostics is an integral part of the healthcare chain and comes into play prior to taking medical decisions. Thanks to our medical vision, we consider the patient and their disease as the starting point for our strategy. We have been working closely with clinicians for many years in order to better understand and anticipate their needs. In 2012, Dr. Mark Miller, a world-renowned medical clinician, researcher and microbiologist, joined bioMérieux as Chief Medical Officer. His broad expertise in our field will help reinforce our medical vision across all our activities, from upstream research to providing products for biologists and clinicians.

What about bioMérieux’s international development?

Our geographic portfolio, which is balanced between mature and emerging markets, greatly contributed to our competitiveness in 2012. Emerging countries account for nearly 30% of our sales and our double-digit growth in these regions offsets the relative stagnation of our traditional markets in Europe and the United States. China provides the perfect example – with growth of over 40%, it is now the Group’s third largest subsidiary, two years ahead of our forecasts!

In addition to this dynamic internationalization, which is essential for our development, global public health remains a priority. Therefore, we will maintain our operations in countries undergoing major economic difficulties so that we can continue to respond to their needs.

bioMérieux is celebrating its 50th year in 2013: how do you approach this milestone?

I am naturally pleased and very proud of our accomplishments over the last 50 years. Above all, as we look to the future, we feel confident about the next ten years. Our strategy is extremely focused on our areas of specialization: clinical microbiology, industrial applications and specialized immunoassays with very high sensitivity opening up new applications that allow improved standards of care, by providing earlier detection of diseases. Our 2012 results once again confirm the strength of our model, despite a challenging economic environment. Our solid operating performance has been made possible largely due to the experience gained over these last 50 years, and the long-term vision we have always upheld. We have successfully developed innovative solutions to respond to medical and public health challenges, built an outstanding international network to distribute them, acquired and developed successful companies, and forged first class international scientific partnerships. Being pioneers is an integral part of our history, and we have every intention of continuing on this path, relying on our rich bioindustrial heritage and the unwavering support of our shareholders.
Our medical vision places the patient and their disease at the heart of our approach.
Our diagnostic solutions must have an impact both individually and collectively, with a demonstrated benefit for the patient, the hospital, the healthcare system and the community in general. For example, our identification tests for resistant micro-organisms, such as the tests in the VITEK® range, allow the prescription of targeted, effective treatment that shortens hospital stays and enables better management of the antibiotic arsenal, thereby helping combat antimicrobial resistance while controlling healthcare costs.

This medical vision also extends to industry. By ensuring the microbiological quality of agri-food and pharmaceutical products, we help prevent health risks and protect consumers.

We are committed to listening to laboratories and clinicians. We work with them to develop diagnostic tools that provide medical value and economic relevance, with the aim of protecting public health and contributing to the sustainability of healthcare systems.
bioMérieux benefits from a particularly competitive products and services offer which expanded once again across all ranges in 2012. This balanced portfolio allows us to meet the expectations of biologists in emerging as well as mature countries.

bioMérieux gives priority to clinical value and economic efficiency of its products in order to improve laboratory productivity while also controlling healthcare spending.

As a world leader in clinical and industrial microbiology and a differentiated player in the fields of immunoassays and molecular biology, bioMérieux confirms the relevance of its strategic positioning.

2012 witnessed the successful integration of AES and ARGENE, with the alignment of product offerings, coordination of sales teams and merging of distribution channels. As a result, bioMérieux’s high medical value offering in the clinical sector is even stronger. In industrial applications, the alliance between AES and bioMérieux constitutes the largest offering on the market today.
Clinical microbiology represents 51% of sales, and with around 42% of market share, we clearly stand out as global leader in this field.

Our understanding of leadership, however, goes beyond the notion of market share and brings with it certain responsibilities. Since our offering of products and services is one of the largest available today, I believe we must be drivers of innovation to anticipate our customers’ needs and support them in their particular complex work. Through multi-technology, cutting-edge solutions and an expanded service offering, our ambition is to reduce time to results even further, streamline workflows and improve laboratory efficiency. As both pioneers and leaders in our business, we intend to transform microbiology to fully live up to our commitment to public health.

We are at the forefront in the fight against infectious diseases, since microbiology is our core business.
EXCELLENT DYNAMICS FOR FMLA®

With organic growth of 21%, the FMLA® (Full Microbiology Laboratory Automation) range for complete automation of microbiology laboratories confirmed its potential. This year also saw the launch of the third version of Myla®, which helps optimize microbiology laboratory workflows and consolidate data, converting them into rapidly actionable information for better treatment decisions. This third version offers important new features for clinical laboratories, especially for blood culture testing and may also be used for industrial applications.

THE RISE OF MASS SPECTROMETRY

The mass spectrometry range for the identification of bacteria and fungi saw further expansion with the launch of VITEK® MS Plus, which enables VITEK MS customers to extend their use of the system beyond routine daily identification, for conducting research or building a proprietary data base.

EXPANSION OF THE VIDAS® RANGE

VIDAS® 3, the new generation of this automated platform, was presented during the Journées Internationales de Biologie in November in Paris. With enhanced automation and improved traceability, this instrument is especially well suited to high medical value tests, small series and confirmation tests and received an enthusiastic, promising response from biologists. This launch should also allow to speed up the development of the VIDAS range in emerging countries.

Updated and enhanced in 2012, the VIDAS® menu now features 99 parameters, including:

- VIDAS® ANTI-HCV for the diagnosis of hepatitis C. With this new CE marked test, bioMérieux now provides a complete offering for viral hepatitis (A, B and C);
- VIDAS® D-Dimer Exclusion™ II authorized by the U.S. FDA. When combined with a clinical probability assessment, this test, considered an international reference, allows physicians to exclude suspected deep vein thrombosis and/or pulmonary embolism in non-hospitalized patients, within 20 minutes;
- VIDAS® Galectin-3, an innovative marker for chronic heart failure. This new high medical value test, which extends the VIDAS® cardiovascular disease test menu, was CE-marked.
4,600 NEW INSTRUMENTS SOLD

bringing to 69,400 the number of bioMérieux systems installed worldwide

SUCCESS FOR MOLECULAR DIAGNOSTICS EMERGENCY PANEL

The Multi Well System panel of emergency tests in the ARGENE range experienced strong development in 2012. This panel combines different molecular tests, targeting sepsis, severe respiratory infections, digestive infections and meningitis. It is particularly useful for managing emergency syndromes, enabling fast medical and treatment decisions for patients.

SUCCESS STORIES

COMBATTING BACTERIAL RESISTANCE

bioMérieux has expanded its offering of products to fight bacterial resistance with the European launch of a chromogenic culture medium for the detection of carbapenemase-producing (ultra-resistant) Enterobacteriaceae: chromID® CARBA.

BIOMÉRIEUX PERFORMANCE SOLUTIONS™

To help customers address the challenge of an increasingly complex regulatory environment, bioMérieux has launched bioMérieux Performance Solutions for:

- Workflow analysis to optimize overall lab performance;
- Training on products, applications and scientific subjects;
- Quality and compliance: environmental monitoring, systems qualification, methods validation and Quality Control monitoring.
Industrial applications, which now account for more than 20% of the Group’s business, grew by nearly 28% in euros following the consolidation of AES. Organic sales growth rose by 7.6%, with a remarkable 41% surge in the Emerging 7* countries.

With the AES product portfolio, bioMérieux offers the broadest range on the market today, making it possible – much like FMLA® for clinical applications – to provide complete laboratory automation, from sample preparation through to final results.

IN A DYNAMIC GLOBAL MARKET, BIOMÉRIEUX CONTINUALLY ENHANCED ITS PRODUCT LINES

FOR THE AGRI-FOOD INDUSTRY:

- The VIDAS® LPT test for the rapid identification of _Listeria_. This test, which uses highly innovative recombinant phage protein technology, rounds out an offering of particularly critical tests in the agri-food and environmental sector: VIDAS® UP E. coli O157 and VIDAS® UP Salmonella.

FOR THE PHARMACEUTICAL INDUSTRY:

- The VITEK® MS system for the identification of bacteria and fungi using mass spectrometry is equipped with a specific data base for industrial and pharmaceutical applications. This instrument experienced a very successful launch.

* Brazil, China, India, Indonesia, Mexico, Russia and Turkey
A VETERINARY ADVENTURE

2012 saw the launch of the new veterinary diagnostics activity which is true to the Mérieux tradition, with “no borders” between human and veterinary medicines. The new solutions to be developed will make it possible to combat animal diseases and zoonoses while contributing to the prudent use of antibiotics in veterinary medicine, with major implications for human health.

Through this new activity based on AES expertise, bioMérieux will provide solutions across the entire agri-food chain, “from stable to table.”

BUILDING OUR COSMETICS OFFERING

bioMérieux has developed a dedicated unit to meet the specific needs of the cosmetic industry. Diagnostic systems based on cytometry, which allow rapid microbiological testing, open especially interesting prospects for this industry.

NEW INTERNATIONAL CERTIFICATIONS FOR BIOMÉRIEUX INDUSTRY

In 2012, bioMérieux obtained new validations for its products from international reference institutions. As an acknowledgement of the excellence of the Company’s products, such certifications also represent a recognition of quality for customers. Methods for the detection and enumeration of Campylobacter in food products – VIDAS® Campylobacter and Campy Food Agar – received certification, as did the VITEK® 2 Compact Gram Positive cards designed for food safety testing.

ANIMAL HEALTH SUCCESS

The ADIAVET™ Schmallenberg virus PCR detection kit, which was designed by AES/ADIAGENE teams in response to a sanitary emergency impacting European livestock including cattle, sheep or goats in 2012, received validation from the French Agency for Food Safety (ANSES, Maisons-Alfort, France).

The kit, which allows highly accurate detection of the presence of the Schmallenberg virus in just a few hours, is being used by accredited French public veterinary laboratories as part of the outbreak monitoring plan.
The environment we work in is undergoing sweeping changes in science and technology, providing wonderful opportunities for our field, diagnostics, and for which we must foster partnerships in all areas of research. We have therefore forged long-term collaborations with major French and international research organizations. For our clinical activities, in 2012 we initiated a collaboration with the Geneva University Hospitals. This partnership with Professor Schrenzel’s teams allows us to validate our approaches by giving us access to a first-class clinical environment. It complements the major scientific and technological agreements we have entered into with the Institut Pasteur and the French Atomic Energy Commission (CEA) by strengthening our medical vision inherent to our projects.
As bioMérieux celebrates its 50th year, innovation is more than ever a decisive factor driving competitiveness for the company's future development.

From its beginnings as a pioneer in microbiology, bioMérieux has grown to become world leader. Building on its extensive experience, the Company has expanded its competences by integrating new knowledge and complementary technologies that enrich its original expertise so that it can continuously offer new solutions and act as a force for change in the field of diagnostics.

**bioMérieux devotes considerable resources to its innovation strategy:**

- with nearly 11% of sales invested in 70 research programs and over 1,000 employees working at 17 R&D sites worldwide.

bioMérieux relies on the powerful lever of innovative scientific and technology partnerships with French and international researchers, thanks to nearly 25 collaboration agreements and 5 joint research laboratories with the hospital community.

**ALL THESE RESOURCES ARE APPLIED TO MEETING A TWO-FOLD OBJECTIVE:**

- Strengthening the medical value of the solutions provided to clinical laboratories and clinicians, and meeting quality requirements for industrial microbiological controls;

- Continuously improving the efficiency and productivity of laboratories, thus contributing to their transformation.

In 2012, 19 new products were introduced across all product ranges. bioMérieux teams actively contributed to the consolidation of the portfolio of products under development and to preparing the launch of strategic platforms planned for 2013: VIDAS® 3, the new generation of VIDAS®, as well as a new blood culture system, and an incubator incorporating innovative imaging technologies. Efforts have been stepped up in microbial genetic sequencing and mass spectrometry, which are particularly promising technologies. The year 2012 also witnessed new scientific partnerships and growing collaborations with the hospital community, which are essential to obtain clinical validation for various R&D projects.
NEW ADVANCES IN SEQUENCING

In October, bioMérieux signed a Letter of Intent with the Genome Institute at Washington University (St. Louis, Missouri, U.S.) in the field of microbial genetic sequencing. This partnership seeks to build a database by linking the genetic sequences of pathogenic agents to their phenotypic characteristics (identification, virulence and resistance) in order to develop new knowledge in microbiology for laboratories, clinicians and researchers.

This unprecedented initiative will be based on bioMérieux’s exceptional proprietary culture collection of about 90,000 microbial strains. It should ultimately lead to a new application of sequencing applied to the field of microbiology, which will be particularly valuable from a medical standpoint.

REINFORCING OUR CLINICAL RESEARCH ACTIVITIES

As an essential part of bioMérieux’s innovation strategy, the clinical research agreement with the Geneva University Hospitals became fully operational in 2012. The agreement allows the company to validate new approaches by providing access to a first-class clinical environment.

This collaboration, initiated in 2011 for three years, focuses on clinical microbiology, with two types of projects:

- applied research for high medical value microbiology tests. In 2012, a project for the characterization of mycobacteria using the MALDI-TOF VITEK® MS mass spectrometry system was initiated and should enable the identification of 40 species of mycobacteria. Similarly, teams are working on the characterization of microbial flora in patients receiving mechanical ventilation, with the long-term goal of creating simple tests for the early recognition of patients at risk of developing pneumonia;

- the evaluation of new bioMérieux platforms prior to their launch.

A NEW CLASS OF ULTRASENSITIVE IMMOANOASSAYS

In November, bioMérieux and the American company Quanterix announced they had entered into a strategic agreement that gives bioMérieux worldwide exclusive rights to Quanterix’s Simoa™ ultrasensitive immunoassay technology in clinical laboratories and for industrial applications. Under the agreement, Quanterix will deliver a new instrument and consumables based on its Simoa™ technology, and bioMérieux will develop ultrasensitive and multiplex assays on the platform.

This immunoassay technology offers important potential in fields that require extremely high sensitivity – both for existing markers (for example, in myocardial infarction diagnostics, for the measurement of troponin or, in infectious diseases, with sensitivity comparable to that of molecular biology) and for new markers, which are not always possible to measure using current conventional immunological methods.

By developing a new class of immunoassays, bioMérieux and Quanterix are leading the way for this remarkable technology to make a difference in patients’ lives.
CONTRIBUTING TO SYNDROMIC MEDICINE

bioMérieux plans to develop new diagnostic tools to adopt a syndromic approach to medicine in order to direct the physician’s choices early on rather than \textit{a posteriori}. The goal is to offer very broad diagnostic panels that, upon a patient’s arrival, allow very quick testing of a large number of possibilities to rapidly determine care choices. Teams at the research centers of Grenoble and Verniolle (France) are working on automated and decentralized molecular solutions, based in particular on the platform under development with Biocartis.

A first example is the development of tests for the emergency detection of severe infectious diseases, such as healthcare-associated infections, acute respiratory infections, septicemia and meningitis.

SIGNIFICANT PROGRESS IN THERANOSTICS

bioMérieux made important progress in the field of personalized medicine in 2012. An application for Pre-Market Approval was filed with the U.S. Food and Drug Administration (FDA) for a molecular theranostic test to detect two BRAF V600 gene mutations found in several cancers, including melanoma. bioMérieux and GSK are collaborating for the development of a companion test within the scope of their May 2010 partnership agreement. It is designed for patients with metastatic melanomas who test positive for the BRAF V600 gene mutation in order to help oncologists select the most appropriate treatment. This high medical value test enables decisions based on a patient’s capacity to respond to treatment, thus contributing to personalized care.

FIRST STONE LAID FOR NEW R&D BUILDING AT THE LA BALME (FRANCE) SITE

This project took shape out of a desire to bring together specialists in microbiology, engineering and information technology and promote synergy among multidisciplinary teams. Some 200 employees will work at this “microbiology of the future” site, which is expected to be operational by late 2013.
We want to be Brazilian in Brazil, Chinese in China and Indian in India, for long-term integration in the countries where we are working. This allows us to meet their local public healthcare needs.

THIERRY BERNARD
Corporate Vice President, Global Commercial Operations
Since our foundation, bioMérieux has been an international company, progressively building a remarkable network of subsidiaries and distributors. The Group has established operations in emerging countries such as China and Brazil, often well in advance, and today its global outreach is a source of stability and competitive edge.

Thanks to this geographic expansion, the products and solutions resulting from bioMérieux’s R&D programs are distributed to biologists worldwide. In a context of global economic uncertainty, this strategy drives sales, and the Group’s performance in emerging countries offsets slower growth in more mature countries that may be facing drastic healthcare spending cuts.

In 2012, sales were driven by a strong performance in emerging countries, confirming once again the effectiveness of this international development strategy. Emerging countries account for almost 30% of sales, with organic growth averaging 17% in markets that hold considerable long-term potential for clinical and industrial applications alike.

bioMérieux intends to pursue this strategy of international expansion, which saw the creation of two new commercial subsidiaries in 2012, in Malaysia and Vietnam. Beyond its commercial presence, one of the distinctive features of bioMérieux’s strategy is to establish sustainable operations in countries where the Group works. This is accomplished through acquisitions, such as the 60% interest acquired in 2012 in RAS Lifesciences, a molecular biology based diagnostics company in India, and through agreements with local R&D partners, such as cooperation for the early detection of certain cancers with the University of Fudan in Shanghai. In addition, the Group’s activity is structured around areas of specialization that encompass R&D, production and sales, as exemplified by the Pudong Campus in China.

The major trends observed in recent years continued in 2012: robust growth in emerging countries, stagnation in North America, and regional contrasts in Europe where sales trended downward in Southern Europe compared with a solid performance in Northern Europe.

Thanks to the extensiveness of its offering of manual and automated solutions, bioMérieux is able to meet different needs from one country to the next: tests with high medical value for mature countries, and equipment markets for emerging countries. It is interesting to note that industrial applications performed well worldwide, a sign that preventing microbiological contamination risks is becoming a public health priority in numerous countries.

**2012 HIGHLIGHTS**

**2 NEW SUBSIDIARIES**
- bioMérieux Vietnam in Hanoi
- bioMérieux Malaysia in Kuala Lumpur

**7 SUBSIDIARIES IN SOUTHEAST ASIA**

**A WORLDWIDE NETWORK OF 41 COMMERCIAL SUBSIDIARIES**

**BIOMÉRIEUX CHINA:**

**3RD LARGEST SUBSIDIARY AFTER THE UNITED STATES AND FRANCE**

China, home to 1.3 billion people, with 67,000 hospitals and health facilities for a rapidly growing diagnostics market of 2 billion euros, already larger than that of France

**ACQUISITION OF A 60% INTEREST IN RAS Lifesciences, AN INDIAN MOLECULAR BIOLOGY BASED DIAGNOSTICS COMPANY**

making it possible to meet needs in India and ultimately in other emerging countries as well.
**ASIA-PACIFIC: VIGOROUS GROWTH**

Asia-Pacific lived up to its full potential where sales rose by 17% in the region, with remarkable growth rates in China (+41%) and India (+18%). Across the region, where the need for laboratory equipment is extensive, instrument sales progressed by 31%. In clinical applications, growth was spurred by the microbiology and VIDAS® immunoassay ranges, while industrial application sales climbed 25%.

bioMérieux’s product ranges are particularly well suited to meeting China’s need for infectious disease diagnostics. Strong progress was made in clinical microbiology, with manual and automated antibiotic susceptibility tests; in immunoassays, with the VIDAS system; and in the agri-food sector, with food safety and quality solutions.

In India, bioMérieux intends to build a leadership position in automated clinical microbiology, broadening the market penetration of VIDAS in immunoassays, and rolling out the AES offering in agri-food applications.

**NORTH AMERICA: STABILITY**

In North America (22% of the consolidated total), sales remained stable in a tense market environment, the result of a “wait and see” attitude linked to the implementation of Obama’s healthcare reform, a trend towards laboratory consolidation, and the establishment of Accountable Care Organizations.

Sales growth in industrial applications drove the business, with reagents and services witnessing strong growth rates in the agri-food market. The new, highly extensive offering that combines bioMérieux and AES solutions was very well received by customers in industry.

In clinical applications, the VIDAS range showed good results driven by the success of high medical value parameters, in particular the VIDAS® B.R.A.H.M.S PCT test, which is especially useful for evaluating the prognosis of sepsis.

**LATIN AMERICA: SOLID PERFORMANCE**

In Latin America, sales increased by nearly 7%, boosted by the Group’s performance in Mexico (+14%) and Argentina (+9%). In Brazil, faster growth in the fourth quarter enabled sales to end the year up slightly, despite the high 18% prior year basis of comparison and a sharp downturn in the economy.

Microbiology reagents led growth in clinical applications, while industrial applications enjoyed robust growth in nearly all countries.

**EUROPE MIDDLE EAST AFRICA: SALES UP SLIGHTLY**

Sales in the Europe / Middle East / Africa zone were up slightly for the year, with considerable differences from one region to the next.

Demand remained vigorous in the Eastern Europe, Middle East and Africa zone, particularly in South Africa and Russia (where sales doubled), bringing sales growth for the year to 15% and supporting the company’s development in this zone.

In a challenging economic environment, sales in Western Europe eased back somewhat. Robust demand in Germany, the United Kingdom and the Benelux countries helped to offset most of the impact of the difficult market conditions prevailing in Southern European countries and France, where the move towards laboratory consolidation continues.

In Southern European countries, the downward trend in sales continued throughout the year as a direct consequence of government austerity measures.
AES IN THE MIDDLE EAST

Having won a bid from the Kuwaiti Ministry of Health, bioMérieux delivered 30 systems for culture media preparation and sample preparation to public hospital laboratories in Kuwait in 2012.

INTRODUCTION OF THE AES RANGE IN BRAZIL

resulted in sales exceeding expectations for products that complete bioMérieux’s current offering in the country and allow total automation of industrial microbiological control laboratories.

VIDAS®, 20 YEARS AND GOING STRONG

the installed base increased by nearly 1,000 systems and confirmed demand for high medical value parameters with, for example, double-digit growth of VIDAS® PCT in the United States.

SUCCESS STORIES

*Unless indicated otherwise, growth in sales is at constant exchange rates and scope of consolidation

THE ARGENE RANGE SELECTED IN CHILE

Four of the principal private hospitals in Chile chose to adopt molecular biology tests in the ARGENE range for the real-time detection of respiratory viruses. Combined with the easyMAG® system, these tests provide a molecular diagnostics solution that is particularly efficient and suited to emergency situations in these hospitals during the winter season.
Our pioneering commitment in the fight against infectious diseases and our dedication to improving public health brings with it certain responsibilities. The expertise we have developed over the last 50 years is applied to benefit the communities with whom we interact. We believe that upholding our Corporate Responsibility means taking action to preserve the health and environment of people everywhere, including for future generations, as well as contributing to more equitable access to healthcare, and promoting our employees’ professional development.
As a global public health player, bioMérieux places patients and, more broadly, people, at the heart of its activities. This priority is the natural focus of bioMérieux’s CORPORATE RESPONSIBILITY approach, structured around THREE KEY COMMITMENTS:

- **SOCIETAL**, by developing solutions that will contribute to preserving the health of future generations and improving access to quality diagnostics for the most disadvantaged patients;

- **SOCIAL**, by promoting employees’ development and preparing them to adapt to a rapidly changing world;

- **ENVIRONMENTAL**, by adopting a bioindustrial policy that respects the environment for the sustainable protection of the health of individuals and communities.
Responsibility to society

Highlights

A corporate sponsorship budget of €2 MILLIONS IN 2012 essentially to support the Fondation Mérieux and the Fondation Christophe and Rodolphe Mérieux.

A RANGE OF MOLECULAR TESTS UNDER DEVELOPMENT for research applications for the Indian market, for the detection of tropical diseases and specific pathologies.

WHO ACCREDITATION of the Grenoble molecular biology site for the production of tests to measure HIV viral load.

Improving access to quality diagnostics for the most disadvantaged patients

True to its public health missions and as part of its corporate sponsorship approach, bioMérieux supports the work of the Fondation Mérieux and the Fondation Christophe and Rodolphe Mérieux. In the field, these two independent family foundations fight infectious diseases affecting developing countries, in particular by improving their diagnostic capacity. The Fondation Christophe and Rodolphe Mérieux, under the aegis of the Institut de France, is the reference shareholder of the Institut Mérieux.

Thanks to the support of bioMérieux and other partners, the foundations have successfully carried out a number of initiatives in developing countries:

- Today they are active in 8 countries: Haiti, Mali, Madagascar, Lebanon, Tajikistan, China, Laos and Cambodia. Projects are underway in Bangladesh and Brazil.
- Their concerted efforts have led to the creation of 8 reference laboratories, the Rodolphe Mérieux Laboratories, which are dedicated to training biologists, diagnosing diseases specific to these countries, and supporting applied research. A number of clinical laboratories have also been renovated and their personnel been trained.
- Through the Dr. Christophe Mérieux Prize, worth €500,000, the Fondation Christophe and Rodolphe Mérieux encourages research in developing countries. The 2012 prize was awarded to Dr. Firdausi Qadri, Director of the Center for Vaccine Sciences diseases (ICDDR,B) in Bangladesh, for her remarkable research on infectious enteric pathogens, which represent a devastating burden for developing countries.
ENSURING QUALITY DIAGNOSTICS AT AN AFFORDABLE PRICE IN EMERGING COUNTRIES

One of bioMérieux’s objectives is to provide access to diagnostics based on cutting-edge technologies at an affordable price to populations in emerging countries. To move closer to this goal, in 2012 bioMérieux acquired RAS LifeSciences, a molecular biology based diagnostics company in India. bioMérieux will develop and ensure local production of diagnostic tests to meet specific needs in India and neighboring countries by giving them access to a particularly effective technology, which is not sufficiently available in these regions today. Molecular tests for tuberculosis and tropical diseases as well as tests to measure viral load for patients living with hepatitis and HIV will as a result be distributed more broadly in emerging countries in the medium term.

The creation of two new subsidiaries in Malaysia and Vietnam also helps fulfill bioMérieux’s commitment to public health. By setting up directly in countries where healthcare systems are in the midst of being built, the Company will be better positioned to assess their specific needs and provide effective support for their healthcare policies and efforts to fight infectious diseases.

FIGHTING BACTERIAL RESISTANCE

BIOMÉRIEUX PARTNER TO WORLD SEPSIS DAY

bioMérieux has been committed to combating sepsis for many years. In October 2012, the Company lent its support to World Sepsis Day. This severe infection, which affects over 20 million people each year, is a major cause of mortality, especially in intensive care units. Due to the aging of the population and growing resistance to antibiotics, the incidence of sepsis is increasing steadily.

World Sepsis Day was organized in 70 countries and aimed to raise public awareness of this often little understood yet widespread disease, and to improve prevention and patient care.

It is important to remember that early diagnosis of sepsis is a key factor in patient survival and that the rapidity of testing allows the determination of appropriate antibiotic therapy preventing the development of the disease.
RESPONSIBILITY TO THE WORKFORCE

HIGHLIGHTS

239
JOBS CREATED
in 2012

49%
WOMEN

51%
MEN

32%<35 years of age,
32% between 35 and 45 years,
37%>45 years

120
YOUNG PEOPLE
with apprenticeship / work-study
contracts in France, representing
4.3% OF THE WORKFORCE

9
COMPANY-WIDE AGREEMENTS
signed in 2012 in France

CREATING AND PRESERVING JOBS

In 2012, the Group created 239 jobs, 83 of which are based in France and sought to maintain employment in subsidiaries affected by the economic crisis, in particular in Southern European countries.

The Group has 7,285 full-time equivalent employees, compared with 7,077 at the end of 2011.

Over the last five years, the total workforce has increased by 19%, respecting gender equality and balancing the age pyramid. Particular emphasis is placed on the employment of young people and retaining seniors in the workforce.
AN AMBITIOUS TRAINING POLICY

In 2007, bioMérieux created an in-house university in order to prepare employees to adapt to changes in their working environment and their jobs while allowing the Group to reach its strategic objectives. Each year, the Company invests in continuous training and goes well beyond meeting legal requirements.

Five years after it opened its doors, bioMérieux University offers a large range of training programs, which are cross-functional or targeted specifically to different functions.

One example is the bioMérieux Manager Essentials training program for employees in a supervisory role. In 2012, this program represented over 17,000 hours of training, or an average of 16 hours per manager.

Programs specific to each function – such as Marketing Excellence, Project Manager Essentials, Manufacturing Essentials, Regulatory Affairs Essentials and Sales Capabilities – were organized frequently across the Group worldwide.

Individual training plans tailored to meet each employee’s needs were also implemented. In 2012, the average number of hours of training reached 27 hours per employee in France, 25.5 hours in the United States and 38 hours in China.

Product training was provided to 1,500 employees in 2012.

PROTECTING HEALTH IN THE WORKPLACE

- The commitment of the Group’s senior management was demonstrated through the publication of the Global Health, Safety, Environment Management System Manual, which was signed by the CEO and sets out the organization and implementation of activities in connection with Health Safety & the Environment.

- An agreement on health in the workplace was entered into in France with a focus on three areas: arduous work, work organization and psychological risks.

- In North America, a pilot healthcare program was implemented for employees, offering health check-ups, early cancer screening and medical and nutritional advice.
RESPONSIBILITY TO THE ENVIRONMENT

Respecting both the environment and its resources to preserve the health of the communities where the Company operates, particularly for future generations, is a priority for bioMérieux. The BIOMERIEUX GOES GREEN environmental initiative introduced in 2008 continues to gain ground each year, thanks to strong support from the Group’s employees who have embraced this initiative.

bioMérieux’s commitment is focused on five key priorities: energy, water, paper, waste and emissions, with the goal of reducing the environmental impact of the Group’s activities in all these areas.

HIGHLIGHTS

SIGNIFICANTLY REDUCING WATER CONSUMPTION

Water is used by bioMérieux primarily in the manufacturing of its products, in refrigeration facilities and for cooling during production processes. The Company favors closed-loop cooling systems and is vigorously pursuing a policy to replace first-generation once-through cooling systems. bioMérieux regularly analyses its wastewater and, in 2012, invested at the Craponne and Marcy l’Etoile sites (France) to improve the quality of its effluents before their discharge into municipal systems.

IMPROVING ENERGY EFFICIENCY

bioMérieux has implemented a program to optimize and reduce energy consumption. Prior to the design, construction and renovation of buildings, simulations assess the energy efficiency of lighting, heating and ventilation systems as well as comfort during the summer months. The new R&D building planned for the La Balme site in France is being developed in line with these eco-design principles (HQE* certification obtained for the programming and design phases).

During 2012, the Marcy l’Etoile site continued the modernization of its cold production facilities, particularly with the installation of liquid nitrogen freeze dryers, leading to energy savings of 60 to 70%. In addition, the site in Grenoble (France) has improved the energy performance of its air handling units.

At the same time as optimizing its energy consumption, bioMérieux has made a commitment to use “green” electricity to cover around 50% of its...
electricity needs over the 2013 – 2015 period for two of its productions sites which are the largest users of energy today. The subsidiaries also participate in this approach, and 100% of electricity consumed by bioMérieux in Austria and in Canada comes from hydraulic power.

LIMITING PAPER CONSUMPTION

All bioMérieux sites and subsidiaries have introduced initiatives to reduce paper consumption and to promote the use of recycled paper. For product package inserts and instructions for use, bioMérieux has continued the conversion to electronic files available online, implementing this approach in all countries where the electronic format is accepted by regulatory authorities. From 2008 to the end of 2012, paper consumption was reduced by 40% in France and over 30% in the United States.

OPTIMIZING WASTE MANAGEMENT

For many years, bioMérieux has optimized waste management, concentrating in particular on waste reduction at the source, developing recycling and energy recovery, and consistently implementing good practices for waste sorting.

ECO-DESIGN FOR PRODUCTS

From the early stages of development, bioMérieux applies an eco-design approach to both products and their packaging to improve their energy performance and reduce the volume of waste at the source. Thus, the new packaging of susceptibility testing products in the Etest® range launched in 2012 brings a double benefit, by consuming less energy during storage (at 2° to 8°C) while the implementation of electronic instructions for use contributed to a 30% reduction in packaging volumes.

REDUCING EMISSIONS

To reduce its greenhouse gas emissions, bioMérieux has adopted a proactive policy to decrease travel-related emissions by using, whenever possible, new alternative means of communication. The Company also encourages employees to carpool and use public transportation.

To decrease emissions generated when providing technical assistance to customers using bioMérieux instruments, bioMérieux implements alternatives that make it possible to cut back on travel by engineers, thereby limiting the Company’s carbon footprint. The development of the VILINK® remote solution allows customers a way to resolve issues and receive preventive maintenance via a highly secure, rapid connection. This service covers the VITEK® 2, VITEK® MS, PREVI® Isola and Myla® product lines among others.
CORPORATE GOVERNANCE

BOARD OF DIRECTORS

The Board, chaired by Jean-Luc Belingard, met 6 times in 2012.

It is comprised of 9 members:

- Jean-Luc Belingard - Chairman and CEO
- Alexandre Mérieux - Directeur Général Délégué
- Alain Mérieux
- Michel Angé
- Philippe Archinard
- Harold Boël
- Marie-Hélène Habert
- Georges Hibon
- Michele Palladino

COMMITTEES OF THE BOARD OF DIRECTORS

The Audit Committee met 6 times in 2012. It is comprised of Michel Angé, its chairman, Harold Boël and Georges Hibon.

The Human Resources Committee: Nominations and Compensation met twice in 2012. It is comprised of Alain Mérieux, its chairman, Michele Palladino and Michel Angé.
GENERAL MANAGEMENT

STRATEGY COMMITTEE
This committee is comprised of Alain Mérieux, Jean-Luc Belingard and Alexandre Mérieux.

MANAGEMENT COMMITTEE
The Management Committee, chaired by Jean-Luc Belingard, is responsible for implementing the company’s strategy decided by the Board of Directors. It meets once every three months.

AS OF DECEMBER 31, 2012, IT IS COMPRISED OF:
1 Jean-Luc Belingard - Chairman and CEO
2 Michel Baguenault - Corporate Vice President, Human Resources and Communications
3 Thierry Bernard - Corporate Vice President, Global Commercial Operations
4 Jean-Marc Durano - Corporate Vice President, Industrial Microbiology Unit
5 Steve Harbin - Corporate Vice President, Manufacturing and Supply Operations, Quality Management, Regulatory Affairs & Information Systems
6 François Lacoste - Corporate Vice President, Immunoassay Unit
7 Marc Mackowiak - Chief Executive Officer, bioMérieux, Inc.
8 Mark Miller - Chief Medical Officer
9 Alexandre Mérieux - Corporate Vice President, Microbiology Unit
10 Alain Pluquet - Chief Technology Officer, Corporate Vice President, Innovation and Systems Unit
11 Henri Thomasson - Corporate Vice President, Finance
12 Stefan Willemsen - Corporate Vice President, Business Development, Legal Affairs and Intellectual Property

R&D COMMITTEE
In 2011, an R&D Committee was created. Chaired by Jean-Luc Belingard, its role is to assess new innovative orientations and to optimize the resources to carry R&D projects through to a successful conclusion.
**NET SALES** (in millions of euros)

Despite a challenging economic environment, sales increased by 6.8% at constant exchange rates, including 3.7% organic growth.

**BREAKDOWN OF SALES BY REGION**

Sales growth was led by a strong performance in emerging countries (+17%), validating the Company’s geographic expansion strategy. With sales up 41%, China is now the Group’s third largest subsidiary.

**BREAKDOWN OF SALES BY TECHNOLOGY**

bioMérieux is a leader in clinical and industrial microbiology, sectors that represent over 70% of sales. In immunology (23% of sales) the VIDAS® range is undergoing rapid growth in high medical value tests and emerging markets.

**OPERATING INCOME BEFORE NON-RECURRING ITEMS**

(Operating income before non-recurring items reached €260 million, and represented 16.6% of sales. The margin was adversely impacted by the currency effect on sales; otherwise it would have stood at 17.1% for the year.

* including R&D tax credits

**NET INCOME** (in millions of euros)

Net income amounted to €134 million of consolidated sales, after non-recurring items representing a net expense of €25 million.

* After non-recurring items primarily concerning BioTheranostics.
R&D EXPENSES (in millions of euros)
As the Company prepares to launch 3 innovative platforms in 2013, R&D expenses represented nearly 11% of sales. They stood at €169 million for the year, an 8% increase at constant exchange rates.

FREE CASH FLOW* (in millions of euros)
bioMérieux continued to generate significant free cash flow while also increasing its capital expenditure.
* Free cash flow before acquisition and dividends.

CAPITAL EXPENDITURE (in millions of euros)
Expenditure was mainly for the instrument base, continuous improvement and increase of the industrial tool capacity, continuation of the “Global ERP” project as well as technology acquisition. The total amount invested over the year represented 8.4% of sales.

FINANCIAL STRUCTURE (in millions of euros)
Net debt stood at €48 million at December 31, 2012, representing less than 5% of shareholders’ equity. The Company enjoys a solid financial position to pursue its strategic ambitions.

TOTAL WORKFORCE* AS AT DECEMBER 31ST
The increase in the number of employees primarily reflects the strengthening of production and sales & marketing teams.
* In full-time equivalents.
<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Sales</strong></td>
<td>1,569.8</td>
<td>1,427.2</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>-755.6</td>
<td>-666.1</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>814.2</td>
<td>761.1</td>
</tr>
<tr>
<td>Other operating income</td>
<td>23.9</td>
<td>20.7</td>
</tr>
<tr>
<td>Selling and marketing expenses</td>
<td>-294.7</td>
<td>-264.5</td>
</tr>
<tr>
<td>General and administrative expenses</td>
<td>-114.3</td>
<td>-107.6</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>-168.7</td>
<td>-152.1</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>-577.7</td>
<td>-524.2</td>
</tr>
<tr>
<td>Operating income before non-recurring items</td>
<td>260.4</td>
<td>257.6</td>
</tr>
<tr>
<td>Other non-recurring income (expenses)</td>
<td>-25.4</td>
<td>-12.2</td>
</tr>
<tr>
<td><strong>Operating income</strong>*</td>
<td>235.0</td>
<td>245.3</td>
</tr>
<tr>
<td>Cost of net financial debt</td>
<td>-6.4</td>
<td>-4.4</td>
</tr>
<tr>
<td>Other financial items</td>
<td>-4.9</td>
<td>-3.3</td>
</tr>
<tr>
<td>Income tax</td>
<td>-89.4</td>
<td>-77.2</td>
</tr>
<tr>
<td><strong>Net income of consolidated companies</strong>*</td>
<td>134.2</td>
<td>160.5</td>
</tr>
<tr>
<td>Attributable to the minority interests</td>
<td>-0.1</td>
<td>2.3</td>
</tr>
<tr>
<td><strong>Attributable to the parent company</strong>*</td>
<td>134.4</td>
<td>158.2</td>
</tr>
<tr>
<td>Basic net income per share*</td>
<td>3.41 €</td>
<td>4.01 €</td>
</tr>
<tr>
<td>Diluted net income per share*</td>
<td>3.41 €</td>
<td>4.01 €</td>
</tr>
</tbody>
</table>

* After non-recurring items primarily concerning bioTheranostics.
### ASSETS in millions of euros

<table>
<thead>
<tr>
<th>Category</th>
<th>NET 12/31/2012</th>
<th>NET 12/31/2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NON-CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intangible assets</td>
<td>157.0</td>
<td>184.4</td>
</tr>
<tr>
<td>Goodwill</td>
<td>313.1</td>
<td>334.3</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>386.7</td>
<td>367.0</td>
</tr>
<tr>
<td>Financial assets</td>
<td>34.7</td>
<td>26.9</td>
</tr>
<tr>
<td>Other non-current assets</td>
<td>29.6</td>
<td>31.5</td>
</tr>
<tr>
<td>Deferred tax assets</td>
<td>21.0</td>
<td>28.2</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>942.2</strong></td>
<td><strong>972.2</strong></td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventories and work in progress</td>
<td>245.9</td>
<td>217.1</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>433.4</td>
<td>447.1</td>
</tr>
<tr>
<td>Other operating receivables</td>
<td>71.2</td>
<td>50.4</td>
</tr>
<tr>
<td>Tax receivable</td>
<td>20.7</td>
<td>19.6</td>
</tr>
<tr>
<td>Non-operating receivables</td>
<td>8.4</td>
<td>1.0</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>65.6</td>
<td>42.7</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>845.4</strong></td>
<td><strong>777.9</strong></td>
</tr>
<tr>
<td>Assets held for sale</td>
<td>45.7</td>
<td>12.0</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>1,833.2</strong></td>
<td><strong>1,762.2</strong></td>
</tr>
</tbody>
</table>

### LIABILITIES AND SHAREHOLDERS’ EQUITY

<table>
<thead>
<tr>
<th>Category</th>
<th>12/31/2012</th>
<th>12/31/2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SHAREHOLDERS’ EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Share capital</td>
<td>12.0</td>
<td>12.0</td>
</tr>
<tr>
<td>Additional paid-in capital &amp; Reserves</td>
<td>1,047.1</td>
<td>925.1</td>
</tr>
<tr>
<td>Net income for the year</td>
<td>134.4</td>
<td>158.2</td>
</tr>
<tr>
<td><strong>TOTAL EQUITY BEFORE MINORITY INTERESTS</strong></td>
<td><strong>1,193.4</strong></td>
<td><strong>1,095.4</strong></td>
</tr>
<tr>
<td><strong>MINORITY INTERESTS</strong></td>
<td>6.8</td>
<td>8.1</td>
</tr>
<tr>
<td><strong>TOTAL SHAREHOLDERS’ EQUITY</strong></td>
<td><strong>1,200.2</strong></td>
<td><strong>1,103.4</strong></td>
</tr>
</tbody>
</table>

| **NON-CURRENT LIABILITIES**               |            |            |
| Net financial debt - long-term            | 9.8        | 12.6       |
| Deferred tax liabilities                  | 46.3       | 41.2       |
| Provisions                                | 42.2       | 33.2       |
| **TOTAL**                                 | **98.3**   | **87.0**   |

| **CURRENT LIABILITIES**                   |            |            |
| Net financial debt - short-term           | 104.2      | 161.3      |
| Provisions                                | 11.0       | 14.0       |
| Accounts payable                          | 145.1      | 142.6      |
| Other operating liabilities               | 217.5      | 198.9      |
| Tax liabilities                           | 20.2       | 27.3       |
| Non-operating liabilities                 | 23.8       | 27.7       |
| **TOTAL**                                 | **521.8**  | **571.8**  |
| Liabilities related to assets held for sale| 13.0       | 0.0        |
| **TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY**| **1,833.2**| **1,762.2**|
## CONSOLIDATED CASHFLOW STATEMENT

<table>
<thead>
<tr>
<th>In millions of euros</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income of consolidated companies</td>
<td>134.2</td>
<td>160.5</td>
</tr>
<tr>
<td>Adjustements</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Cost of net financial debt</td>
<td>6.4</td>
<td>4.4</td>
</tr>
<tr>
<td>- Other financial items</td>
<td>4.9</td>
<td>3.3</td>
</tr>
<tr>
<td>- Current income tax expense</td>
<td>89.4</td>
<td>77.2</td>
</tr>
<tr>
<td>- Operating depreciation and provisions on assets</td>
<td>94.4</td>
<td>85.3</td>
</tr>
<tr>
<td>- Non-recurring items</td>
<td>25.4</td>
<td>12.2</td>
</tr>
<tr>
<td><strong>EBITDA (before non-recurring items)</strong></td>
<td><strong>354.8</strong></td>
<td><strong>342.8</strong></td>
</tr>
<tr>
<td>Other non current operating gains/losses (w/o exceptionnal depreciations and capital gains/losses)</td>
<td>-2.9</td>
<td>-11.2</td>
</tr>
<tr>
<td>Other financial items (w/o accruals &amp; disposal of financial assets)</td>
<td>-0.5</td>
<td>-0.2</td>
</tr>
<tr>
<td>Operating provisions for contingencies</td>
<td>8.0</td>
<td>-0.7</td>
</tr>
<tr>
<td>Change in fair value of financial instruments</td>
<td>-0.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Share-based payments</td>
<td>-2.5</td>
<td>2.0</td>
</tr>
<tr>
<td><strong>Elimination of other gains and losses without any impact on cash or operations</strong></td>
<td><strong>1.7</strong></td>
<td><strong>-9.9</strong></td>
</tr>
<tr>
<td>Increase in inventories</td>
<td>-32.0</td>
<td>-18.5</td>
</tr>
<tr>
<td>Change in requirements in accounts receivable</td>
<td>6.5</td>
<td>-29.2</td>
</tr>
<tr>
<td>Decrease in accounts payable</td>
<td>6.0</td>
<td>-0.1</td>
</tr>
<tr>
<td>Change in other operating working capital</td>
<td>-6.7</td>
<td>-1.0</td>
</tr>
<tr>
<td>Increase in operating working capital</td>
<td>-26.2</td>
<td>-48.8</td>
</tr>
<tr>
<td>Income tax paid</td>
<td>-76.2</td>
<td>-65.7</td>
</tr>
<tr>
<td>Other non operating working capital</td>
<td>3.0</td>
<td>0.8</td>
</tr>
<tr>
<td>Change in non-current assets</td>
<td>1.4</td>
<td>-2.5</td>
</tr>
<tr>
<td>Other cashflows from operations</td>
<td>-98.0</td>
<td>-116.2</td>
</tr>
<tr>
<td><strong>Net cash flow from operations</strong></td>
<td><strong>258.5</strong></td>
<td><strong>216.6</strong></td>
</tr>
<tr>
<td>Purchase of property, plant and equipment</td>
<td>-127.4</td>
<td>-102.1</td>
</tr>
<tr>
<td>Proceeds on fixed asset disposals</td>
<td>8.2</td>
<td>6.7</td>
</tr>
<tr>
<td>Purchase of financial assets / Disposals of financial assets</td>
<td>-12.9</td>
<td>-3.7</td>
</tr>
<tr>
<td>Impact of changes in the scope of consolidation</td>
<td>1.7</td>
<td>-226.1</td>
</tr>
<tr>
<td><strong>Net cash flow from (used in) investment activities</strong></td>
<td><strong>-130.4</strong></td>
<td><strong>-325.2</strong></td>
</tr>
<tr>
<td>Purchases and proceeds of treasury stocks</td>
<td>0.8</td>
<td>-2.8</td>
</tr>
<tr>
<td>Dividends to shareholders</td>
<td>-38.7</td>
<td>-38.7</td>
</tr>
<tr>
<td>Dividends to minority interests</td>
<td>-0.5</td>
<td>0.0</td>
</tr>
<tr>
<td>Cost of net financial debt</td>
<td>-6.4</td>
<td>-4.4</td>
</tr>
<tr>
<td>Change in confirmed financial debt</td>
<td>-11.4</td>
<td>102.1</td>
</tr>
<tr>
<td><strong>Net cash flow from (used in) financing activities</strong></td>
<td><strong>-56.2</strong></td>
<td><strong>56.2</strong></td>
</tr>
<tr>
<td><strong>NET CHANGE IN CASH AND CASH EQUIVALENTS</strong></td>
<td><strong>71.9</strong></td>
<td><strong>-52.4</strong></td>
</tr>
<tr>
<td><strong>ANALYSIS OF NET CHANGE IN CASH AND CASH EQUIVALENTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net cash and cash equivalents at the beginning of the year</td>
<td>-19.2</td>
<td>34.0</td>
</tr>
<tr>
<td>Impact of currency changes on net cash and cash equivalents</td>
<td>-0.2</td>
<td>-0.9</td>
</tr>
<tr>
<td>Net change in cash and cash equivalents</td>
<td>71.9</td>
<td>-52.3</td>
</tr>
<tr>
<td>Net cash and cash equivalents at the end of the year</td>
<td>52.5</td>
<td>-19.2</td>
</tr>
</tbody>
</table>
THE BIOMÉRIEUX SHARE

SHARE PRICE PERFORMANCE IN 2012*

* Indexes rebased on bioMérieux’s stock price as at December 31, 2011 (€55.24)

BREAKDOWN OF CAPITAL
AS AT DECEMBER 31, 2012

THE BIOMÉRIEUX SHARE

Listed on July 6, 2004, the bioMérieux share is part of the following indexes: CAC Mid 60®, SBF 120®, CAC Mid & Small®, CAC All-tradable® and CAC All-Share®.

The Company is listed on the compartment A of Eurolist and is eligible for the Deferred Settlement Service (SRD).

bioMérieux is also part of certain sustainability indexes: Gaia Index 2012/2013, FTSE4Good Index and ASPI Eurozone®.

At the end of December 2012, the closing price of the bioMérieux share was €72 and the market capitalization reached 2.8 billion euros.

9,875,761 shares were traded on the Nyse Euronext platform in 2012.

2013 CALENDAR OF EVENTS

January 23rd: Investor day and 2012 Q4 business review
March 13th: 2012 results
April 23rd: 2013 Q1 business review
May 29th: Shareholders meeting
July 18th: 2013 Q2 business review
September 4th: 2013 first-half results
October 23rd: 2013 Q3 business review

INVESTOR RELATIONS CONTACT

Isabelle Tongio
Phone: 33 (0)4 78 87 22 37
Email: investor.relations@biomerieux.com

The Reference Document approved by the AMF is available upon request or on our Web site: www.biomerieux-finance.com
**ANTIBIOTIC SUSCEPTIBILITY TESTING**
Determines the growth of a bacterium in the presence of antibiotics and classifies it as susceptible, resistant or intermediate.

**BIOMARKER / MARKER**
Any indicator (nucleic acids, enzymes, metabolites and other types of molecules: histamines, hormones, proteins, etc.) present in the body or excreted by it as a biological response to a physiological or pathological condition. A biomarker can make it possible to identify the presence, the effect and/or the measurement of specific phenomena, such as:
- the rapid or early detection of a disease, before the first symptoms appear,
- the progression of a disease,
- the impact of a drug or treatment.

**BLOOD CULTURE**
An essential blood test in the field of infectious diseases. It is carried out by taking a sample of venous blood, which is then cultured to reveal the presence or absence of germs.

**CAMPYLOBACTER**
A genus of Gram-negative bacteria that can cause food poisoning.

**CARBAPENEMASES**
β-lactamase type enzymes which hydrolyze carbapenems, a class of antibiotics with extended-spectrum activity, mainly used for the treatment of multi-drug resistant bacterial infections.

**CHROMOGEN**
Molecule that gives off a color under certain conditions. When incorporated into a culture medium, it reveals the presence of an enzyme specific to a given bacteria, thereby indicating the bacteria that is cultured.

**CYTOMETRY**
The counting of cells.

**ENUMERATION**
Counting how many microbes (bacteria or fungi) are present in a sample.

**ENTEROBACTERIA**
A family of bacilli (bacteria) revealed by Gram-negative staining, which are aerobic or anaerobic (they can live and reproduce with or without oxygen).

**FLOW CYTOMETRY**
A technique that consists of passing a stream of cells, particles or molecules at high speed through a laser beam. The light re-emitted (by diffusion or fluorescence) enables the population to be classified and sorted according to several criteria.

**HEALTHCARE-ASSOCIATED INFECTION**
An infection that patients acquire during the course of receiving treatment for other conditions within a hospital or healthcare setting.

**IMMUNOASSAYS**
Detection of infectious agents (bacteria, viruses, parasites) and pathogen markers based on an antigen/antibody reaction.

**IN VITRO DIAGNOSTICS**
Analysis of biological samples (urine, blood, etc.) performed outside the human body.

**LISTERIA**
A genus of bacteria that can cause listeriosis, an infectious disease that is potentially serious in newborn babies, pregnant women and individuals with low resistance.

**MASS SPECTROMETRY**
Technique used to identify a molecule and determine its chemical structure by analyzing the mass and the charge of its ions.

**MICROBIOLOGY**
Study of microorganisms. bioMérieux uses culture-based microbiology methods for the growth of bacteria from biological fluids, food and pharmaceutical samples. The bacteria are subsequently identified and their susceptibility to antibiotics tested in certain cases.

**MOLECULAR BIOLOGY**
Technique that can detect a bacterium, virus, yeast, parasite or a biomarker through the presence of DNA or RNA genetic sequences in a sample.

**PATHOGEN**
That which causes or can cause disease.

**PHAGE RECOMBINANT PROTEIN**
Bacteriophage tail protein that has been obtained by a biological process. Bacteriophages: highly specific viruses that only infect bacteria. They are used for the targeted capture of bacteria and to isolate them from a sample.

**SEPSIS**
A widespread infection characterized by the presence of bacteria in the bloodstream (viruses or fungi can also cause sepsis) and the deterioration of the patient’s general condition as a result of the infection (host response).

**THERANOSTICS**
The association of a diagnostic test with a therapy. The foundation of personalized medicine.
Thanks to all of the bioMérieux employees who contributed to the Annual Report photos.